Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
In Vitro Activity
100%
ABC294640
100%
Sphingosine Kinase 2 Inhibitors
100%
Cancer Activity
100%
SphK2
60%
Sphingolipid Metabolism
40%
Non-small Cell Lung Cancer Patients
40%
Targeted Therapy
40%
United States
20%
Ceramide
20%
Lung Cancer
20%
First-in-class
20%
5-year Survival
20%
Cell Apoptosis
20%
Cell Cycle Arrest
20%
Poor Survival
20%
Non-small Cell Lung Cancer Cells
20%
Cancer Cases
20%
Human Lung Cancer Cell Line
20%
Lung Cancer Patients
20%
Tumor Inhibition
20%
Therapeutic Regimen
20%
Promising Strategies
20%
Anticancer Agents
20%
Apoptotic Cells
20%
New Drug Targets
20%
Growth in Vitro
20%
Recent Introduction
20%
Lipid Analysis
20%
NewHope
20%
Ceramide Species
20%
Dihydroceramide
20%
Radiotherapeutics
20%
Medicine and Dentistry
In Vitro
100%
Non Small Cell Lung Cancer
100%
Sphingosine Kinase 2
100%
Ceramide
22%
Lung Cancer
22%
Targeted Therapy
22%
Sphingolipid Metabolism
22%
Tumor Progression
11%
Cancer Cell
11%
Survival Rate
11%
Programmed Cell Death
11%
Cancer
11%
Hope
11%
Cell Cycle Arrest
11%
Anticarcinogen
11%
Immunotherapy
11%
Cell Cycle Checkpoint
11%
Lipidomics
11%
Lung Cancer Cell Line
11%
Gefitinib
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Opaganib
100%
Sphingosine Kinase 2
100%
Ceramide
22%
Sphingolipid
22%
Lung Cancer
22%
Tumor Growth
11%
Survival Rate
11%
Anticarcinogen
11%
Immunotherapy
11%
Gefitinib
11%